Author:
Wülfing C.,Bögemann M.,Goebell P. J.,Hammerer P.,Machtens S.,Pfister D.,Schwentner C.,Steuber T.,von Amsberg G.,Schostak M.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Aggarwal R, Harris A, Formaker C et al (2014) Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer 12(5):e167–e172
2. Angelergues A, Efstathiou E, Gyftaki R et al (2018) Results of the FLAC European database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor–targeted agents. Clin Genitourin Cancer.
https://doi.org/10.1016/j.clgc.2018.02.016
3. Angelergues A, Maillet D, Flechon A et al (2014) Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). JCO Clin Cancer Inform 32(suppl 4):282a
4. Armstrong A, Garrett-Mayer ES, Yang YC et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396–6403
5. Attard G (2017) A phase IV, randomised double-blind placebo-controlled study of continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naïve metastatic castrations-resistant prostate cancer. J Clin Oncol 35(suppl):5004a
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献